Prevalence of neutralizing antibodies against SARS-CoV-2 using a rapid serological test in health workers of a Spanish Department of Health in Alicante (Spain) before the booster dose of the vaccine
Copyright © 2024 The Author(s). Published by Elsevier España, S.L.U. All rights reserved..
AIM: To study the prevalence of neutralizing antibodies in healthcare workers and healthcare support personnel after the administration of the second dose of the BNT162b2 vaccine (Pfizer-BioNTech).
MATERIALS AND METHODS: In December 2021, we undertook a study in the Health Department in Orihuela, Alicante (Spain), which consists of 1500 workers. We collected demographic variables about the study participants, and we performed a "point-of-care" immunochromatography test to measure the presence of neutralizing antibodies (OJABIO® SARS-CoV-2 Neutralizing Antibody Detection Kit, manufactured by Wenzhou OJA Biotechnology Co., Ltd. Wenzhou, Zhejiang, China) before the administration of the third dose of the vaccine.
RESULTS: We obtained complete information about 964 (64%) workers, which consisted of 290 men and 674 women. The average age was 45,8 years (min. 18, max. 68) and the average time since the last dose of the vaccine was 40,5 weeks (min. 1,71, max. 47,71). A total of 131 participants (13,5%) had suffered infection by SARS-CoV-2 confirmed using RT-PCR. The proportion of participants who showed presence of neutralizing antibodies was 38,5%. In the multivariable analysis, the time since the last dose of the vaccine (aOR week: 1,07; 95%CI: 1,04; 1,09) and previous infection by SARS-CoV-2 (aOR: 3,7; 95CI: 2,39; 5,63) showed a statistically significant association with the presence of neutralizing antibodies.
CONCLUSIONS: The time since the administration of the last dose of the vaccine and the previous infection by SARS-CoV-2 determined the presence of neutralizing antibodies in 38,5% of the healthcare workers and support workers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:224 |
|---|---|
| Enthalten in: |
Revista clinica espanola - 224(2024), 4 vom: 28. Apr., Seite 197-203 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Montagud, A C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rceng.2024.02.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369132858 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369132858 | ||
| 003 | DE-627 | ||
| 005 | 20240408232505.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.rceng.2024.02.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM369132858 | ||
| 035 | |a (NLM)38423384 | ||
| 035 | |a (PII)S2254-8874(24)00036-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Montagud, A C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence of neutralizing antibodies against SARS-CoV-2 using a rapid serological test in health workers of a Spanish Department of Health in Alicante (Spain) before the booster dose of the vaccine |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a AIM: To study the prevalence of neutralizing antibodies in healthcare workers and healthcare support personnel after the administration of the second dose of the BNT162b2 vaccine (Pfizer-BioNTech) | ||
| 520 | |a MATERIALS AND METHODS: In December 2021, we undertook a study in the Health Department in Orihuela, Alicante (Spain), which consists of 1500 workers. We collected demographic variables about the study participants, and we performed a "point-of-care" immunochromatography test to measure the presence of neutralizing antibodies (OJABIO® SARS-CoV-2 Neutralizing Antibody Detection Kit, manufactured by Wenzhou OJA Biotechnology Co., Ltd. Wenzhou, Zhejiang, China) before the administration of the third dose of the vaccine | ||
| 520 | |a RESULTS: We obtained complete information about 964 (64%) workers, which consisted of 290 men and 674 women. The average age was 45,8 years (min. 18, max. 68) and the average time since the last dose of the vaccine was 40,5 weeks (min. 1,71, max. 47,71). A total of 131 participants (13,5%) had suffered infection by SARS-CoV-2 confirmed using RT-PCR. The proportion of participants who showed presence of neutralizing antibodies was 38,5%. In the multivariable analysis, the time since the last dose of the vaccine (aOR week: 1,07; 95%CI: 1,04; 1,09) and previous infection by SARS-CoV-2 (aOR: 3,7; 95CI: 2,39; 5,63) showed a statistically significant association with the presence of neutralizing antibodies | ||
| 520 | |a CONCLUSIONS: The time since the administration of the last dose of the vaccine and the previous infection by SARS-CoV-2 determined the presence of neutralizing antibodies in 38,5% of the healthcare workers and support workers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticuerpos neutralizantes | |
| 650 | 4 | |a Booster dose | |
| 650 | 4 | |a COVID-19 vaccine | |
| 650 | 4 | |a Dosis de refuerzo | |
| 650 | 4 | |a Healthcare worker | |
| 650 | 4 | |a Neutralizing antibodies | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Serological rapid test | |
| 650 | 4 | |a Test serológico rápido | |
| 650 | 4 | |a Trabajadores sanitarios | |
| 650 | 4 | |a Vacuna COVID-19 | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Llenas-García, J |e verfasserin |4 aut | |
| 700 | 1 | |a Moragues, R |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Bernabeu, A |e verfasserin |4 aut | |
| 700 | 1 | |a Alcocer Pertegal, M J |e verfasserin |4 aut | |
| 700 | 1 | |a García Gómez, F J |e verfasserin |4 aut | |
| 700 | 1 | |a Gamayo Serna, A M |e verfasserin |4 aut | |
| 700 | 1 | |a García Morante, H |e verfasserin |4 aut | |
| 700 | 1 | |a Caballero, P |e verfasserin |4 aut | |
| 700 | 1 | |a Tuells, J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista clinica espanola |d 2013 |g 224(2024), 4 vom: 28. Apr., Seite 197-203 |w (DE-627)NLM21591063X |x 2254-8874 |7 nnns |
| 773 | 1 | 8 | |g volume:224 |g year:2024 |g number:4 |g day:28 |g month:04 |g pages:197-203 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rceng.2024.02.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 224 |j 2024 |e 4 |b 28 |c 04 |h 197-203 | ||